Orchestra BioMed Q2 FY26 net loss widens 23% to $24.1 million; revenue drops to $88,000

Reuters2026/08/10 20:17

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Orchestra BioMed posted Q2 net loss attributable to common stockholders of USD 24.1 million, widening 23% year over year; loss per share improved to USD 0.38 from USD 0.50.
Revenue fell to USD 88,000 from USD 836,000 a year earlier, with partnership revenue at no revenue versus USD 667,000.
R&D expense rose 20% to USD 16.6 million on higher clinical trial activity; SG&A declined 7% to USD 5.8 million.
Cash, cash equivalents and marketable securities totaled USD 110 million; net cash used in operating activities and fixed assets was USD 19.6 million.
BACKBEAT trial targets 284 evaluable randomized patients by end-Q3 2026, with primary endpoint data targeted for a Q2 2027 late-breaker; Virtue pivotal trial enrollment continues.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orchestra Biomed Holdings Inc. published the original content used to generate this news brief on August 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Orchestra BioMed Q2 FY26 net loss widens 23% to $24.1 million; revenue drops to $88,000

You may also like

Crypto prices